Literature DB >> 28332219

Targeting Immunotherapy to the Tumor Microenvironment.

Michael Dougan1, Stephanie K Dougan2,3.   

Abstract

Targeting drugs to the tumor microenvironment has long been appreciated as a means of increasing local concentrations and decreasing systemic toxicities. How drug targeting might apply to immune-based therapies is less clear. In this review, we explain the immunology of cancer, with a focus on the principles of in situ vaccination. Certain types of therapies are more amenable to local versus systemic delivery; these include cytokines, adjuvants, radiation, and agents targeting tumor-resident cell populations. Several approaches for targeting the tumor microenvironment are under development. Nanoparticles, peptide or antibody-based delivery, and exploitation of cellular influx are all promising ways to delivery immune modulating compounds to tumors. J. Cell. Biochem. 118: 3049-3054, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  CANCER IMMUNOLOGY; DRUG TARGETING; IMMUNOTHERAPY; TUMOR MICROENVIRONMENT

Mesh:

Substances:

Year:  2017        PMID: 28332219     DOI: 10.1002/jcb.26005

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

1.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

2.  Localized CD47 blockade enhances immunotherapy for murine melanoma.

Authors:  Jessica R Ingram; Olga S Blomberg; Jonathan T Sockolosky; Lestat Ali; Florian I Schmidt; Novalia Pishesha; Camilo Espinosa; Stephanie K Dougan; K Christopher Garcia; Hidde L Ploegh; Michael Dougan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

3.  Antitumor effects of targeted killing of tumor-associated macrophages under photothermal conditions.

Authors:  Bo Wang; Ying Huang
Journal:  Lasers Med Sci       Date:  2021-01-13       Impact factor: 3.161

Review 4.  Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer.

Authors:  Wubin Zheng; Fan Wu; Kai Fu; Guangshun Sun; Guoqiang Sun; Xiao Li; Wei Jiang; Hongyong Cao; Hanjin Wang; Weiwei Tang
Journal:  Onco Targets Ther       Date:  2021-05-06       Impact factor: 4.147

Review 5.  Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.

Authors:  Zhixia Zhou; Zhan Wang; Jie Gao; Zhijuan Lin; Yin Wang; Peipei Shan; Mengkun Li; Tingting Zhou; Peifeng Li
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 6.311

6.  BCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell Stemness.

Authors:  Vasiliki Pelekanou; George Notas; Paraskevi Athanasouli; Konstantinos Alexakis; Fotini Kiagiadaki; Nikolaos Peroulis; Konstantina Kalyvianaki; Errika Kampouri; Hara Polioudaki; Panayiotis Theodoropoulos; Andreas Tsapis; Elias Castanas; Marilena Kampa
Journal:  Front Oncol       Date:  2018-08-07       Impact factor: 6.244

7.  The TNFSF Members APRIL and BAFF and Their Receptors TACI, BCMA, and BAFFR in Oncology, With a Special Focus in Breast Cancer.

Authors:  Marilena Kampa; George Notas; Efstathios N Stathopoulos; Andreas Tsapis; Elias Castanas
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

Review 8.  Understanding and treating the inflammatory adverse events of cancer immunotherapy.

Authors:  Michael Dougan; Adrienne M Luoma; Stephanie K Dougan; Kai W Wucherpfennig
Journal:  Cell       Date:  2021-03-05       Impact factor: 41.582

Review 9.  Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells.

Authors:  Zheng Li; Xuekun Fu; Jie Huang; Peiyuan Zeng; Yuhong Huang; Xinxin Chen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-05-19

10.  Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer.

Authors:  Sayeda Yasmin-Karim; Patrick T Bruck; Michele Moreau; Sijumon Kunjachan; Gui Zhen Chen; Rajiv Kumar; Stephanie Grabow; Stephanie K Dougan; Wilfred Ngwa
Journal:  Front Immunol       Date:  2018-09-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.